$0.24 EPS Expected for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) This Quarter
Brokerages expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to post earnings per share of $0.24 for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $0.50 and the lowest is $0.05. Ionis Pharmaceuticals posted earnings per share of $1.28 during the same quarter last year, which indicates a negative year-over-year growth rate of 81.3%. The company is scheduled to report its next earnings report before the market opens on Wednesday, February 24th.
On average, analysts expect that Ionis Pharmaceuticals will report full-year earnings of ($0.52) per share for the current financial year, with EPS estimates ranging from ($0.64) to ($0.30). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.64) per share, with EPS estimates ranging from ($1.88) to $0.16. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Ionis Pharmaceuticals.
Several research analysts have issued reports on the stock. SVB Leerink decreased their target price on shares of Ionis Pharmaceuticals from $56.00 to $50.00 and set a “market perform” rating for the company in a report on Thursday, November 5th. Cowen upgraded shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, December 15th. UBS Group assumed coverage on shares of Ionis Pharmaceuticals in a research report on Tuesday, December 15th. They issued a “sell” rating and a $34.00 price target for the company. Finally, Morgan Stanley dropped their price target on shares of Ionis Pharmaceuticals from $50.00 to $49.00 and set an “underweight” rating for the company in a research report on Thursday, November 5th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $61.55.
In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 28,333 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, January 26th. The shares were sold at an average price of $63.74, for a total transaction of $1,805,945.42. Following the sale, the chairman now owns 2,021 shares of the company’s stock, valued at approximately $128,818.54. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Stanley T. Crooke sold 1,407 shares of the business’s stock in a transaction dated Thursday, December 17th. The shares were sold at an average price of $50.50, for a total transaction of $71,053.50. Following the transaction, the chairman now directly owns 2,021 shares in the company, valued at approximately $102,060.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 228,660 shares of company stock valued at $12,471,383. Insiders own 2.40% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Nachman Norwood & Parrott Inc purchased a new stake in Ionis Pharmaceuticals during the third quarter worth about $26,000. International Assets Investment Management LLC acquired a new position in Ionis Pharmaceuticals in the fourth quarter valued at approximately $26,000. CWM LLC boosted its holdings in Ionis Pharmaceuticals by 94.3% in the third quarter. CWM LLC now owns 618 shares of the company’s stock valued at $29,000 after purchasing an additional 300 shares in the last quarter. Heritage Wealth Advisors boosted its holdings in Ionis Pharmaceuticals by 99.7% in the fourth quarter. Heritage Wealth Advisors now owns 667 shares of the company’s stock valued at $38,000 after purchasing an additional 333 shares in the last quarter. Finally, Wolff Wiese Magana LLC acquired a new position in Ionis Pharmaceuticals in the fourth quarter valued at approximately $64,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
Featured Story: Compound Interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.